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1121. Barely 50 years ago, the very existence of a primary adenocarcinomaof the esophagus was debated, and this rare tumor was a novelty incomparison with squamous cell esophageal cancer. Yet in one ofthe most dramatic epidemiologic transformations ever recorded,adenocarcinoma has become the predominant form of esophagealcancer, and the incidence of this cancer continues to increase in all
age groups in the United States.1 Although both squamous cell carcinoma and
adenocarcinoma of the esophagus are deadly diseases, the existence of a precursor
lesion (Barrett) for esophageal adenocarcinoma has allowed significant advances in
our understanding of the pathogenesis and natural history of this cancer. Increas-
ingly, early adenocarcinoma is detected either within a surveillance program for
Barrett or fortuitously during an endoscopy to evaluate symptoms of reflux. Many
of these patients have superficial tumors and are cured with surgical resection alone,
disproving previously held concepts that esophageal cancer is systemic and essen-
tially incurable in all patients at the time of diagnosis.
The increasing incidence of esophageal adenocarcinoma and the fact that many
of these patients are otherwise healthy permits an accurate assessment of the natural
history of the disease and the effect of specific therapies on the course of the illness.
Experience at several centers has demonstrated that one of the most important
predictors of both survival and the risk of systemic disease in patients with
esophageal adenocarcinoma is the presence and extent of involved lymph nodes.2-5
Although the current American Joint Committee on Cancer Staging system for
esophageal carcinoma only classifies disease as N0 (no involved nodes) or N1 (1 or
more involved nodes), distinct survival curves can be produced on the basis of the
number, as well as the ratio, of involved to total resected lymph nodes.6,7 The depth
of tumor invasion is also important, but most of the importance relates to the direct
correlation between the depth of invasion and the prevalence of nodal metastases.
In this issue of the Journal, Lerut and colleagues8 examine the influence of
lymph node involvement, and in particular extracapsular tumor extension, on the
survival of patients undergoing primary surgical resection for adenocarcinoma of
the esophagus. All patients in this retrospective study had T3 tumors and had
undergone an R0 resection without neoadjuvant therapy. Similar to data from other
centers, 83% of these patients with transmural tumors had one or more involved
lymph glands, as determined by histologic examination.2,9 Importantly, that means
that 17% of patients with locally advanced tumors did not have any lymph node
metastases, and the 57% 5-year survival in these patients was significantly better
than that of patients who had lymph node metastases.8 We also found that 16% of
patients with transmural tumors had no involved lymph nodes, and the 5-year
survival for this group of patients after en bloc resection alone was 85% in our
experience.2
An interesting aside is that the percentage of patients with locally advanced
tumors without nodal involvement is similar to the percentage of patients who are
found to have a complete pathologic response after neoadjuvant chemoradiotherapy.
Furthermore, the survival in this group is quite similar to the survival reported for
the subgroup of patients with a complete pathologic response in several randomized
trials comparing neoadjuvant chemoradiotherapy plus surgical intervention with
surgical intervention alone.10-12 Recently, Jiao and associates13 have shown that
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patients with lymph node metastases proved by minimally
invasive staging techniques are less likely to have a com-
plete pathologic response to neoadjuvant therapy. Putting
this information together, one might speculate that the sub-
group of patients with a complete pathologic response and
improved survival in the randomized trials of neoadjuvant
therapy might well be those without lymph node metastases,
who would have done well with surgical resection alone.
Thus, pathologic pretreatment staging should be encouraged
in future trials, and potentially misleading subgroup analy-
ses should be avoided.
Lerut and colleagues8 also confirmed what has been
demonstrated in other centers in regard to the importance of
the number of involved lymph nodes.3,7 They found that the
number of positive lymph nodes exhibited a linear effect in
the Cox regression analysis of survival, with increasingly
worse survival as the number of involved nodes increased
up to a maximum of 12. In addition to the importance of the
number of positive nodes, the characteristics of lymph
nodes containing metastatic deposits might also affect sur-
vival. Recently, Dhar and coworkers5 reported that the size
of involved lymph nodes influences survival in patients with
esophageal cancer, and now Lerut and colleagues8 demon-
strate that extracapsular tumor extension within an involved
lymph node is also an important survival determinant. In the
study by Lerut and colleagues, patients with extracapsular
nodal involvement had a significantly worse survival than
that seen in those without nodal involvement or only intra-
capsular nodal involvement. The most compelling argument
in support of the importance of extracapsular nodal involve-
ment was the finding that if patients with only a single
positive lymph node were compared, the 5-year survival in
those with extracapsular tumor extension in the positive node
was significantly worse (33.3%) than it was in those with only
intracapsular nodal involvement (85.7%). This would suggest
that it is not merely that patients with extracapsular nodal
involvement have more advanced disease and more involved
nodes than patients with intracapsular nodal extension. Rather,
it supports the argument that Lerut and colleagues8 put forth:
that extracapsular nodal involvement is an independent nega-
tive prognostic factor in these patients.
Surprisingly, Lerut and colleagues8 found that survival in
patients with only intracapsular nodal involvement was not
significantly different from that in patients with no involved
lymph nodes (40.9% vs 57% at 5 years, respectively). The
number of patients at risk at each time interval is not
provided in the Kaplan-Meier survival plot, but it is likely
that this represents a type II error. This finding also suggests
that most patients with intracapsular nodal involvement had
only a few involved nodes; otherwise one would certainly
expect there to be a significant survival difference compared
with that seen in patients with no involved lymph nodes.
However, because the authors do not provide information
regarding the mean and median number of involved nodes
for patients with intracapsular versus extracapsular nodal
involvement, it is not possible to evaluate this further.
It is also difficult to explain the finding that the 5-year
survival in 14 patients with 1 positive lymph node and
intracapsular tumor involvement was 85.7%.8 This survival
is much greater than the 57% 5-year survival in patients
with no involved nodes and is incongruent with the signif-
icant survival difference between patients with pN0 and
pN1 disease reported by multiple authors, as well as the
findings by some investigators that even micrometastases
detected with immunohistochemical staining adversely af-
fect survival in patients with esophageal cancer.14,15 This
might again reflect a type II error because only 14 patients
had isolated intracapsular nodal involvement.
Thus, although the concept of extracapsular versus intra-
capsular nodal involvement is intriguing and might allow
further stratification of survival in patients with esophageal
cancer and involved lymph nodes, the fact remains that the
current staging system fails to take into account the clear
importance of the number of involved nodes. Once revi-
sions in the staging system have been accomplished that
address the survival differences on the basis of the number
of involved nodes, perhaps further stratification can be made
on the basis of anatomic and histologic characteristics, such
as the presence of capsular invasion or micrometastatic
disease in lymph nodes. Ultimately, it is likely that many of
these relatively crude factors will be replaced or supple-
mented by tumor-specific panels of biologic and molecular
staging markers. In the meantime, physicians involved in
the treatment of patients with esophageal cancer should pay
attention to both the presence and the number of histolog-
ically involved lymph nodes.
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